Abstract
microRNA-199a (miR-199a) is a highly conserved miRNA, always deregulated in numerous human tumors. The results of microarray analysis indicated that miR-199a was frequently downregulated in hepatocellular carcinoma (HCC). The expression levels of miR-199a in 11 pairs of matched HCC neoplastic and adjacent non-neoplastic tissues, 5 HCC cell lines and liver cell line L02 were examined by quantitative real-time PCR analysis. We found miR-199a was significantly down-regulated in HCC tissues when compared with pair-matched adjacent non-tumor tissues. We also found the expression level of miR-199a was also substantially decreased in several human HCC cell lines including SMMC-7721, BEL-7402, BEL-7701, MHCC97H, and HepG2. To investigate the role of miR-199a in tumorigenesis, we developed a lentiviral vector for the expression of pre-miR-199a (Lenti-miR-199a). Lenti-miR-199a inhibited HCC cell proliferation in vitro and in vivo. Compared to parental cells or cells transfected with a control vector, the overexpression of microRNA-199a in the HCC cell lines HepG2 stably was showed to reduce cell proliferation in vitro and in vivo. Luciferase reporter assay revealed the regulation of miR-199a on 3’-UTR of HIF-1α. Further investigation confirmed that miR-199a significantly reduced the endogenous protein level of HIF-1α in hypoxia. MiR-199a inhibits cell proliferation in vitro and in vivo partly through down-regulation of HIF-1α in human HCC. Thus, these studies provide an important new insight into the pathogenesis of human HCC and it may open a new perspective for the development of effective gene therapy for human HCC.
Similar content being viewed by others
Abbreviations
- miRNA:
-
MicroRNA
- HCC:
-
Human hepatocellular carcinoma
- HIF-1α:
-
Hypoxia inducible factor-1α
- CCK-8:
-
Cell Counting Kit-8
- RFP:
-
Red fluorescent protein
References
Pang, R. W., & Poon, R. T. (2007). From molecular biology to targeted therapies for hepatocellular carcinoma: The future is now. Oncology, 72(Suppl 1), 30–44.
Pang, R. W., Joh, J. W., Johnson, P. J., Monden, M., Pawlik, T. M., & Poon, R. T. (2008). Biology of hepatocellular carcinoma. Annals of Surgical Oncology, 15(4), 962–971.
Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6(11), 857–866.
Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs: MicroRNAs with a role in cancer. Nature Reviews Cancer, 6(4), 259–269.
Ambros, V. (2001). microRNAs: Tiny regulators with great potential. Cell, 107(7), 823–826.
Cannell, I. G., Kong, Y. W., & Bushell, M. (2008). How do microRNAs regulate gene expression? Biochemical Society Transactions, 36(pt 6), 1224–1231.
Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The impact of microRNAs on protein output. Nature, 455(7209), 64–71.
Lim, L. P., Lau, N. C., Garrett-Engele, P., et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433(7027), 769–773.
Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.
Saito, Y., Suzuki, H., & Hibi, T. (2009). The role of microRNAs in gastrointestinal cancers. Journal of Gastroenterology, 44(Suppl 19), 18–22.
Iorio, M. V., Visone, R., Di Leva, G., et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer Research, 67(18), 8699–8707.
Jiang, J., Gusev, Y., Aderca, I., et al. (2008). Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clinical Cancer Research, 14(2), 419–427.
Worley, L. A., Long, M. D., Onken, M. D., & Harbour, J. W. (2008). Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Research, 18(3), 184–190.
Chen, X. M. (2009). MicroRNA signatures in liver diseases. World Journal of Gastroenterology, 15(14), 1665–1672.
Chen, R., Alvero, A. B., Silasi, D. A., et al. (2008). Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene, 27(34), 4712–4723.
Krek, A., Grun, D., Poy, M. N., et al. (2005). Combinatorial microRNA target predictions. Nature Genetics, 37(5), 495–500.
Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003). Prediction of mammalian microRNA targets. Cell, 115(7), 787–798.
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004). Human microRNA targets. PLoS Biol, 2(11), e363.
Ke, Q., & Costa, M. (2006). Hypoxia-inducible factor-1 (HIF-1). Molecular Pharmacology, 70(5), 1469–1480.
Van der Groep, P., Bouter, A., Menko, F. H., van der Wall, E., & Van Diest, P. J. (2008). High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Research and Treatment, 111(3), 475–480.
Swinson, D. E., & O’Byrne, K. J. (2006). Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clinical Lung Cancer, 7(4), 250–256.
Unruh, A., Ressel, A., Mohamed, H. G., et al. (2003). The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene, 22(21), 3213–3220.
Kung, A. L., Zabludoff, S. D., France, D. S., et al. (2004). Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell, 6(1), 33–43.
Lee, J. W., Bae, S. H., Jeong, J. W., Kim, S. H., & Kim, K. W. (2004). Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Experimental Molecular Medicine, 36(1), 1–12.
Maxwell, P. H. (2005). The HIF pathway in cancer. Seminars in Cell and Developmental Biology, 16(4–5), 523–530.
Lee, Y. S., & Lee, Y. S. (2006). MicroRNAs: Small but potent oncogenes or tumor suppressors. Current Opinion in Investigational Drugs, 7(6), 560–564.
Rossi, J. J. (2009). New hope for a microRNA therapy for liver cancer. Cell, 137(6), 990–992.
Aravalli, R. N., Steer, C. J., & Cressman, E. N. (2008). Molecular mechanisms of hepatocellular carcinoma. Hepatology, 48(6), 2047–2063.
Visone, R., & Croce, C. M. (2009). MiRNAs and cancer. American Journal of Pathology, 174(4), 1131–1138.
Wang, V., & Wu, W. (2009). MicroRNA-based therapeutics for cancer. Biodrugs, 23(1), 15–23.
Kota, J., Chivukula, R. R., O’Donnell, K. A., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6), 1005–1017.
Castanotto, D., & Rossi, J. J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457(7228), 426–433.
Liu, Q. S., Zhang, J., Liu, M., & Dong, W. G. (2010). Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer. Cancer Science, 101(8), 1807–1812.
Yeo, E. J., Chun, Y. S., Cho, Y. S., et al. (2003). YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute, 95(7), 516–525.
Brown, L. M., Cowen, R. L., Debray, C., et al. (2006). Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Molecular Pharmacology, 69(2), 411–418.
Acknowledgments
This study was supported by a grant from State Major Basic Research Development Program of China (973 Project No. 2010CB933902). We thank Dr. Xi Chen for his technical help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jia, X.Q., Cheng, H.Q., Qian, X. et al. Lentivirus-Mediated Overexpression of MicroRNA-199a Inhibits Cell Proliferation of Human Hepatocellular Carcinoma. Cell Biochem Biophys 62, 237–244 (2012). https://doi.org/10.1007/s12013-011-9263-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-011-9263-8